HBK Sorce Advisory’s Werewolf Therapeutics HOWL Stock Holding History

HBK Sorce Advisory’s Portfolio HOWL Stock Details HOWL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.32K	Hold	13,227	–	–	﹤0.01%	670
2026 Q1	$8.99K	Hold	13,227	–	–	﹤0.01%	661
2025 Q4	$8.1K	Hold	13,227	–	–	﹤0.01%	627
2025 Q3	$23.3K	Hold	13,227	–	–	﹤0.01%	615
2025 Q2	$14.4K	Sell	13,227 -314	-2%	-$323	﹤0.01%	590
2025 Q1	$13.2K	Sell	13,541 -1,816	-12%	-$2.38K	﹤0.01%	586
2024 Q4	$22.7K	Buy	15,357 +1,678	+12%	+$3.42K	﹤0.01%	569
2024 Q3	$29K	Buy	13,679 +452	+3%	+$1.03K	﹤0.01%	571
2024 Q2	$32.3K	Hold	13,227	–	–	﹤0.01%	554
2024 Q1	$85.7K	Sell	13,227 -13,227	-50%	-$77.1K	﹤0.01%	585
2023 Q4	$102K	Hold	26,454	–	–	﹤0.01%	546
2023 Q3	$56.6K	Hold	26,454	–	–	﹤0.01%	549
2023 Q2	$80.7K	Hold	26,454	–	–	﹤0.01%	563
2023 Q1	$68.8K	Buy	+26,454	New	+$78.8K	﹤0.01%	564

Other funds holding HOWL

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

DC Funds Mclean, Virginia $1.25M AUM 26.51% 1-Year Est. Return

Verdad Advisers Boston, Massachusetts $104M AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

HBK Sorce Advisory's HOWL Position: Q2 2026 in Review

HBK Sorce Advisory held its Werewolf Therapeutics (HOWL) position steady in Q2 2026 at 13,227 shares worth $5.32K. The position accounts for ﹤0.01% of the portfolio, ranked #670.

HBK Sorce Advisory first reported a position in HOWL in Q1 2023 and has held it in 14 quarters since. The position peaked at $102K in Q4 2023. 45 funds tracked by Wall St. Rank hold HOWL as of Q2 2026.

HBK Sorce Advisory held 13,227 shares of Werewolf Therapeutics worth $5.32K as of Q2 2026.
HBK Sorce Advisory left its Werewolf Therapeutics share count unchanged in Q2 2026.
Werewolf Therapeutics made up ﹤0.01% of HBK Sorce Advisory's portfolio in Q2 2026, its #670 holding.
HBK Sorce Advisory first reported a position in Werewolf Therapeutics in Q1 2023 and has held it in 14 quarters since.
HBK Sorce Advisory's Werewolf Therapeutics position peaked at $102K in Q4 2023.
45 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q2 2026.

Based on HBK Sorce Advisory's 13F filing for Q2 2026, filed 6 Aug 2026.